MaxCyte, Inc. (MXCT)
| Market Cap | 141.45M -22.0% |
| Revenue (ttm) | 34.37M -0.1% |
| Net Income | -27.98M |
| EPS | -0.26 |
| Shares Out | 103.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,108,161 |
| Open | 1.290 |
| Previous Close | 1.280 |
| Day's Range | 1.250 - 1.420 |
| 52-Week Range | 0.643 - 1.800 |
| Beta | 1.48 |
| Analysts | Strong Buy |
| Price Target | 4.11 (+199.78%) |
| Earnings Date | Nov 10, 2026 |
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engi... [Read more]
Financial Performance
In 2025, MaxCyte's revenue was $33.03 million, a decrease of -14.50% compared to the previous year's $38.63 million. Losses were -$44.63 million, 8.71% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MXCT stock is "Strong Buy." The 12-month stock price target is $4.11, which is an increase of 199.78% from the latest price.
News
MaxCyte Transcript: 2026 Stephens Annual Investment Conference | NASH2026
Akron expands the portfolio across viral and non-viral cell therapy, with revenue synergies expected from 2028. Core growth, rising royalties, and cost controls support a 2027 cash-burn target below $10M and a path toward cash-flow positivity.
MaxCyte Transcript: Stifel 2026 Healthcare Conference 2026
Akron Bio expands reagent offerings and is expected to lift next year’s revenue above $60 million while reducing cash burn to below $10 million. Core markets are stabilizing, with instrument demand, recurring revenue, and large-pharma opportunities supporting expected growth.
MaxCyte to acquire Akron BioProducts for $151.8M
MaxCyte (MXCT) announced that it has entered into a definitive agreement to acquire Akron BioProducts from affiliates of Arcline Investment Management for total consideration of $151.8M. The transacti...
MaxCyte reports Q3 EPS (5c), consensus (8c)
Reports Q3 revenue $10.2M including $8.2M of core revenue and $2.0M of SPL Program-related revenue, consensus $7.47M. “Today, we announced our intention to acquire Akron Bio, a transformational moment...
MaxCyte now sees 2026 revenue ex-items $34.5M, consensus $32.2M
2026 revenue view consists of core revenue of $28M, SPL Program-related revenue of at least $6.5M for the year; SPL Program-related revenue guidance includes both revenue of approximately $4M from…
MaxCyte Earnings Call Transcript: Q3 2026
Q3 revenue rose 49% YoY, with core growth and improved processing assembly demand. The Akron Bio deal would more than double revenue scale, add durable commercial exposure and accelerate the path to profitability.
MaxCyte Earnings release: Q3 2026
MaxCyte released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
MaxCyte Quarterly report: Q3 2026
MaxCyte has published its Q3 2026 quarterly earnings report on November 10, 2026.
MaxCyte Slides: Corporate presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
MaxCyte Slides: Partnership Portfolio presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
MaxCyte Slides: Acquisition presentation
MaxCyte has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
Third Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related reven...
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and co...
MaxCyte to Participate in Three Upcoming Investor Conferences
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and c...
MaxCyte reports preliminary Q3 revenue $8.1M, consensus $7.02M
“Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately 15% year-over-year growth in the secon...
MaxCyte raises FY26 revenue view to $34M from $30M-$32M, consensus $31.45M
The company said, “Core business revenue of approximately $28 million, compared to prior guidance of $25 million to $27 million. SPL Program-related revenue of approximately $6 million for the year,…
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
MaxCyte appoints Kapileshwar as Chief Corporate Development Officer
MaxCyte (MXCT) announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. Kapileshwar joins MaxCyte from Danaher (DHR), where he most recently served as Vice Presiden...
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and c...
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, developme...
MaxCyte reports Q2 EPS (8c), consensus (9c)
Reports Q2 revenue $7.27M, consensus $6.47M. “We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in proces...
MaxCyte Earnings Call Transcript: Q2 2026
Q2 2026 revenue stabilized and exceeded expectations despite prior headwinds, with sequential growth driven by instrument placements and a major Genentech partnership. Operating expenses fell 25% year-over-year, and 2026 guidance was reiterated, supported by a strong cash position and diversified revenue streams.
MaxCyte Earnings release: Q2 2026
MaxCyte released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
MaxCyte Quarterly report: Q2 2026
MaxCyte has published its Q2 2026 quarterly earnings report on August 12, 2026.